Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 995209

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 995209

North America Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome and Other Applications), By Country, Industry Analysis and Forecast, 2020 - 2026

PUBLISHED:
PAGES: 57 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The North America Inhaled Nitric Oxide Market would witness market growth of 6.1% CAGR during the forecast period (2020-2026).

This nitric oxide can be inhaled via the nose or mouth, which helps in relaxing the smooth muscles to broaden all the blood vessels in the oxygenated regions of the lungs. It is mostly utilized together with the ventilator and other components to cure pulmonary hypertension in newborn babies and adults with respiratory problems.

It is clinically proven that nitric oxide gas is effective in enlarging blood vessels to ease down the muscle tension that takes in oxygen more efficiently in the body. Moreover, nitric oxide is mostly utilized in breathing systems like ventilators. The inhaled nitric oxide is regarded as a strong & selective pulmonary vasodilator, which does not reduce systemic vascular tone.

It is considered that INO therapy was effective to enhance oxygenation in newborn babies with persistent pulmonary hypertension of the newborn (PPHN). It is due to its selective pulmonary vasodilator effects, inhaled nitric oxide therapy is a crucial treatment for term newborns with hypoxemic respiratory problems because of PPHN. In 1999, the Food and Drug Administration of the U.S. had first approved Inhaled Nitric Oxide for its usage as a medical gas to cure hypoxic respiratory failure related to the clinical or echocardiographic confirmation of pulmonary hypertension in term and late preterm infants. Afterward, inhaled nitric oxide therapy is clinically used to cure PPHN in term and late preterm infants without consensus.

Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The Neonatal Respiratory Treatment market dominated the Canada Inhaled Nitric Oxide Market by Application in 2019, growing at a CAGR of 6 % during the forecast period. The Chronic Obstructive Pulmonary Disease (COPD) market is expected to witness a CAGR of 7.1% during (2020 - 2026).

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.

Scope of the Study

Market Segments covered in the Report:

By Application

  • Neonatal Respiratory Treatment
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Acute Respiratory Distress Syndrome (ARDS)
  • Other Applications

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled

  • Getinge AB
  • Merck Group
  • Halma PLC
  • Linde PLC (Praxair, Inc.)
  • Air Liquide S.A.
  • Beyond Air, Inc.
  • Mallinckrodt PLC (International Minerals and Chemical Corporation)
  • VERO Biotech LLC
  • Nu-Med Plus, Inc.
  • Novoteris, LLC

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Inhaled Nitric Oxide Market, by Application
    • 1.4.2 North America Inhaled Nitric Oxide Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market composition
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Strategies deployed in Inhaled Nitric Oxide Market - Global

Chapter 4. North America Inhaled Nitric Oxide Market by Application

  • 4.1 North America Neonatal Respiratory Treatment Repellent Market by Country
  • 4.2 North America Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Country
  • 4.3 North America Acute Respiratory Distress Syndrome (ARDS) Market by Country
  • 4.4 North America Other Applications Market by Country

Chapter 5. North America Inhaled Nitric Oxide Market by Country

  • 5.1 USA Inhaled Nitric Oxide Market
    • 5.1.1 USA Inhaled Nitric Oxide Market by Application
  • 5.2 Canada Inhaled Nitric Oxide Market
    • 5.2.1 Canada Inhaled Nitric Oxide Market by Application
  • 5.3 Mexico Inhaled Nitric Oxide Market
    • 5.3.1 Mexico Inhaled Nitric Oxide Market by Application
  • 5.4 Rest of North America Inhaled Nitric Oxide Market
    • 5.4.1 Rest of North America Inhaled Nitric Oxide Market by Application

Chapter 6. Company Profiles

  • 6.1 Getinge AB
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Regional Analysis
    • 6.1.4 Research & Development Expense
  • 6.2 Merck Group
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental and Regional Analysis
    • 6.2.4 Research & Development Expense
  • 6.3 Halma PLC
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Research & Development Expense
  • 6.4 Linde PLC (Praxair, Inc.)
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Regional Analysis
    • 6.4.4 Research & Development Expense
    • 6.4.5 Recent strategies and developments:
      • 6.4.5.1 Acquisition and Mergers:
  • 6.5 Air Liquide S.A.
    • 6.5.1 Company Overview
    • 6.5.1 Financial Analysis
  • 6.6 Beyond Air, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Research & Development Expense
    • 6.6.4 Recent strategies and developments:
      • 6.6.4.1 Trials and Approvals:
  • 6.7 Mallinckrodt PLC (International Minerals and Chemical Corporation)
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Segmental and Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Trials and Approvals:
      • 6.7.5.2 Partnerships, Collaborations, and Agreements:
  • 6.8 VERO Biotech LLC
    • 6.8.1 Company Overview
    • 6.8.2 Recent strategies and developments:
      • 6.8.2.1 Trials and Approvals:
  • 6.9 Nu-Med Plus, Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Recent strategies and developments:
      • 6.9.2.1 Partnerships, Collaborations, and Agreements:
  • 6.10. Novoteris, LLC
    • 6.10.1 Company Overview
    • 6.10.2 Recent strategies and developments:
      • 6.10.2.1 Trials and Approvals:

LIST OF TABLES

  • TABLE 1 North America Inhaled Nitric Oxide Market, 2016 - 2019, USD Million
  • TABLE 2 North America Inhaled Nitric Oxide Market, 2020 - 2026, USD Million
  • TABLE 3 North America Inhaled Nitric Oxide Market by Application, 2016 - 2019, USD Million
  • TABLE 4 North America Inhaled Nitric Oxide Market by Application, 2020 - 2026, USD Million
  • TABLE 5 North America Neonatal Respiratory Treatment Repellent Market by Country, 2016 - 2019, USD Million
  • TABLE 6 North America Neonatal Respiratory Treatment Repellent Market by Country, 2020 - 2026, USD Million
  • TABLE 7 North America Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Country, 2016 - 2019, USD Million
  • TABLE 8 North America Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Country, 2020 - 2026, USD Million
  • TABLE 9 North America Acute Respiratory Distress Syndrome (ARDS) Market by Country, 2016 - 2019, USD Million
  • TABLE 10 North America Acute Respiratory Distress Syndrome (ARDS) Market by Country, 2020 - 2026, USD Million
  • TABLE 11 North America Other Applications Market by Country, 2016 - 2019, USD Million
  • TABLE 12 North America Other Applications Market by Country, 2020 - 2026, USD Million
  • TABLE 13 North America Inhaled Nitric Oxide Market by Country, 2016 - 2019, USD Million
  • TABLE 14 North America Inhaled Nitric Oxide Market by Country, 2020 - 2026, USD Million
  • TABLE 15 USA Inhaled Nitric Oxide Market, 2016 - 2019, USD Million
  • TABLE 16 USA Inhaled Nitric Oxide Market, 2020 - 2026, USD Million
  • TABLE 17 USA Inhaled Nitric Oxide Market by Application, 2016 - 2019, USD Million
  • TABLE 18 USA Inhaled Nitric Oxide Market by Application, 2020 - 2026, USD Million
  • TABLE 19 Canada Inhaled Nitric Oxide Market, 2016 - 2019, USD Million
  • TABLE 20 Canada Inhaled Nitric Oxide Market, 2020 - 2026, USD Million
  • TABLE 21 Canada Inhaled Nitric Oxide Market by Application, 2016 - 2019, USD Million
  • TABLE 22 Canada Inhaled Nitric Oxide Market by Application, 2020 - 2026, USD Million
  • TABLE 23 Mexico Inhaled Nitric Oxide Market, 2016 - 2019, USD Million
  • TABLE 24 Mexico Inhaled Nitric Oxide Market, 2020 - 2026, USD Million
  • TABLE 25 Mexico Inhaled Nitric Oxide Market by Application, 2016 - 2019, USD Million
  • TABLE 26 Mexico Inhaled Nitric Oxide Market by Application, 2020 - 2026, USD Million
  • TABLE 27 Rest of North America Inhaled Nitric Oxide Market, 2016 - 2019, USD Million
  • TABLE 28 Rest of North America Inhaled Nitric Oxide Market, 2020 - 2026, USD Million
  • TABLE 29 Rest of North America Inhaled Nitric Oxide Market by Application, 2016 - 2019, USD Million
  • TABLE 30 Rest of North America Inhaled Nitric Oxide Market by Application, 2020 - 2026, USD Million
  • TABLE 31 Key Information - Getinge AB
  • TABLE 32 key Information - Merck Group
  • TABLE 33 key Information - Halma PLC
  • TABLE 34 key Information - Linde PLC
  • TABLE 35 Key information - Air Liquide S.A.
  • TABLE 36 Key information - Beyond Air, Inc.
  • TABLE 37 Key information - Mallinckrodt PLC
  • TABLE 38 Key Information - VERO Biotech LLC
  • TABLE 39 key Information - Nu-Med Plus, Inc.
  • TABLE 40 key Information -Novoteris, LLC

List of Figures

  • FIG 1 Methodology for the research
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!